Replaces Prod. #: ALX-550-320
Peripheral decarboxylase inhibitor. Also inhibits tryptophan hydroxylase and tyrosine hydroxylase. Used with L-DOPA as a Parkinson’s disease therapeutic.
Product Details
| Formula: | C10H15N3O5 . HCl |
| |
| MW: | 293.7 |
| |
| CAS: | 14919-77-8 |
| |
| Purity: | ≥98% |
| |
| Appearance: | Tan solid. |
| |
| Solubility: | Soluble in water. Almost insoluble in 100% ethanol, insoluble in acetone. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | Ambient |
| |
| Use/Stability: | Product is subject to oxidation. Make solutions fresh daily. Store, as supplied, at room temperature for up to 1 year. |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
In vitro cardiac pharmacology of the new histamine H2-receptor agonist amthamine: comparisons with histamine and dimaprit: E. Poli et al.; Agents Actions
40, 44 (1993),
Abstract;
The new potent and selective histamine H2 receptor agonist amthamine as a tool to study gastric secretion: G. Coruzzi et al.; Naunyn Schmiedebergs Arch. Pharmacol.
348, 77 (1993),
Abstract;
Single-dose study of slow release preparation of levodopa and benserazide (Madopar HBS) in Parkinson's disease: M.-H. Marion et al.; Adv. Neurol.
45, 493 (1987),
Abstract;
Astemizole. A review of its pharmacodynamic properties and therapeutic efficacy: D.M. Richards et al.; Drugs
28, 38 (1984),
Abstract;
In vitro and in vivo binding characteristics of a new long-acting histamine H1 antagonist, astemizole: P.M. Laduron et al.; Mol. Pharmacol.
21, 294 (1982),
Abstract;
Levodopa and decarboxylase inhibitors: a review of their clinical pharmacology and use in the treatment of parkinsonism: R.M. Pinder et al.; Drugs
11, 329 (1976),
Abstract;
